Latest Information Update: 30 Jun 2016
At a glance
- Originator Sihuan Pharmaceutical Holdings Group
- Class Antihypertensives; Small molecules
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypertension
Most Recent Events
- 12 Mar 2012 Preclinical trials in Hypertension in China (unspecified route)